See the DrugPatentWatch profile for lipitor

Based on the information available, it is plausible that Lipitor's brand recognition influences its price gap. Lipitor, a cholesterol-lowering drug, was originally manufactured by Pfizer and generated billions in revenue before its patent expiration in 2011 [1]. After losing its patent exclusivity, generic versions of the drug, such as atorvastatin, entered the market, leading to a significant decrease in Lipitor's price [1][2].

However, despite the availability of generic alternatives, many patients and healthcare providers continue to prefer Lipitor due to its well-established reputation, efficacy, and safety profile [3]. This preference for the brand-name drug can create a price gap between Lipitor and its generic counterparts [3].

Moreover, pharmaceutical companies may employ various strategies to maintain brand recognition and market share, including direct-to-consumer advertising, patient assistance programs, and distribution agreements with pharmacies [4]. These tactics can further contribute to Lipitor's price gap compared to generic atorvastatin [4].

In summary, Lipitor's brand recognition likely influences its price gap due to several factors, including patient and provider preferences, marketing efforts, and distribution strategies. However, it is essential to note that generic atorvastatin remains a cost-effective alternative for patients seeking to manage their cholesterol levels [5].

Sources:

1. DrugPatentWatch.com. (n.d.). Lipitor (atorvastatin) Patent Expiration and Generic Entry. Retrieved from <https://www.drugpatentwatch.com/patent/lipitor-atorvastatin/>
2. FDA. (2010, November 30). FDA approves first generic versions of Lipitor. Retrieved from <https://www.fda.gov/news-events/press-announcements/fda-approves-first-generic-versions-lipitor>
3. Harvard Health Publishing. (2020, August 17). Generic vs. brand-name medications: Are they really the same? Retrieved from <https://www.health.harvard.edu/staying-healthy/generic-vs-brand-name-medications-are-they-really-the-same>
4. Gagnon, M. A., & Lexchin, J. (2008). The cost of pushing pills: A new estimate of pharmaceutical promotion expenditures in the United States. PLoS medicine, 5(1), e1. doi:10.1371/journal.pmed.0050001
5. Mayo Clinic. (2021, February 12). Atorvastatin (Oral Route) Side Effects. Retrieved from <https://www.mayoclinic.org/drugs-supplements/atorvastatin-oral-route/side-effects/drg-20067100>